Anagenex
Anagenex is a biotechnology company focused on advancing small molecule drug discovery through a novel, directed evolution platform, having recently closed a $30 million Series A funding round.
Company Leadership
Anagenex has recently expanded its leadership team with notable appointments. Adrian Schreyer, Ph.D., has been appointed as the Chief Technology Officer. Ryan Kruger, a veteran in pharmaceutical R&D, has been appointed as the Chief Scientific Officer. Additionally, the company has strengthened its board of directors with the appointments of Robert Forrester and Isaac Ro.
Collaborations
Anagenex has announced a significant multi-target collaboration to discover small molecule therapeutics for multiple indications. This collaboration aims to leverage the company's expertise in directed evolution and small molecule drug discovery to develop new treatments.
Funding
Anagenex successfully closed a $30 million Series A funding round led by Catalio. This funding is intended to advance the company's small molecule drug discovery efforts utilizing their novel, directed evolution platform. The substantial financial support underscores investor confidence in Anagenex's innovative approach.
Company Location and Contact Information
Anagenex is located at 20 Maguire Rd Suite 302, Lexington, MA 02421. Interested parties can reach the company by phone at (978) 444-2649.